Cargando…
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
Essential thrombocythemia (ET) is currently diagnosed either by the British Committee of Standards in Haematology (BCSH) criteria that are predominantly based on exclusion and not necessarily on bone marrow (BM) morphology, or the World Health Organization (WHO) criteria that require BM examination...
Autores principales: | Gisslinger, H, Jeryczynski, G, Gisslinger, B, Wölfler, A, Burgstaller, S, Buxhofer-Ausch, V, Schalling, M, Krauth, M-T, Schiefer, A-I, Kornauth, C, Simonitsch-Klupp, I, Beham-Schmid, C, Müllauer, L, Thiele, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858583/ https://www.ncbi.nlm.nih.gov/pubmed/26710883 http://dx.doi.org/10.1038/leu.2015.360 |
Ejemplares similares
-
Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
por: Gisslinger, H, et al.
Publicado: (2017) -
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
por: Schalling, Martin, et al.
Publicado: (2017) -
Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'
por: Gisslinger, H, et al.
Publicado: (2017) -
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia
por: Buxhofer‐Ausch, Veronika, et al.
Publicado: (2020) -
Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018)